Screening, Treatment Cuts Breast Cancer Deaths in Half
Conclusions: Our results revealed that PCSK9 inhibition may moderately improve breast cancer outcomes while having no harmful effects in tumor-bearing mice. PMID: 31110521 [PubMed]
Publication date: Available online 21 May 2019Source: Biocatalysis and Agricultural BiotechnologyAuthor(s): Lamia Abou El-Kassem, Usama W. Hawas, Sahar El-Souda, Eman F. Ahmed, Wail El-Khateeb, Walid FayadAbstractForty-eight endophytic fungal strains were isolated and purified from ten Egyptian medicinal plants and their culture broth extracts were explored for HCV protease inhibitory activity and cytotoxicity. The ethyl acetate extracts of Alternaria alternata PGL-3, Cochlibolus lunatus PML-17, Nigrospora sphaerica EPS-38, followed by Emerecilla nidulans RPL-21 showed the most potent inhibition of HCV NS3/4A protease with...
Publication date: Available online 22 May 2019Source: Journal of Molecular StructureAuthor(s): Mogedda E. Haiba, Ebtehal S. Al-Abdullah, Nesreen S. Ahmed, Hazem A. Ghabbour, Hanem M. AwadAbstractThe present study presents easy and rapid methods to synthesize new benzo[h]chromene and benzo[h] quinoline derivatives. Cytotoxic evaluations of most of the examined compounds indicated that they had significant cytotoxic activities against HepG-2 (human cancer cells) and MCF-7 (breast cancer cells). Compounds 4 and 11 had stronger cytotoxic activity against HepG-2 human cancer cells than the reference drug Doxorubicin. All the ex...
ConclusionThese results indicate that 24R,25(OH)2D3 shows promise in treatment of breast cancer by stimulating tumor apoptosis and reducing metastasis.General significance24R,25(OH)2D3 regulates breast cancer cell survival through ER-associated mechanisms similar to 24R,25(OH)2D3 effects on chondrocytes. Thus, 24R,25(OH)2D3 may modulate cell survival in other estrogen-responsive cell types, and its therapeutic potential should be investigated in ER-associated pathologies.
ConclusionsPrevalence of CRC and BC screening among low-income adults rose in Medicaid expansion states, though increases were significantly higher than those in non-expansion states only for recent CRC screening in VE expansion states. Large-scale improvements in cancer screening may take several years following expansion in access to care.
ConclusionAFT does not increase breast cancer recurrence, with the possible exception of late LRRs for Luminal A patients, but further clinical and preclinical data are required to better clarify this data. The use of AFT should not be discouraged.
Seeing a 93 yo with strong PS and no comorbid illness to limit life expectancy. She has a 3cm ER/PR+ breast cancer, and just refuses surgery for some reason. She'll agree to Tamoxifen and potentially radiation. Any role for XRT here? Just put her on TAM and wait to see if there is progression at any point?
Conditions: Resistant Breast Cancer; Non-metastatic Invasive Breast Cancer Interventions: Drug: Capecitabine; Radiation: Radiotherapy Sponsor: A Bapsi Chakravarthy, MD Not yet recruiting
Condition: Breast Cancer Interventions: Drug: Ipatasertib; Drug: Fulvestrant; Drug: Aromatase Inhibitor; Drug: Palbociclib Sponsors: Massachusetts General Hospital; Genentech, Inc. Not yet recruiting
Condition: Breast Cancer Stage Intervention: Drug: nab-paclitaxel Sponsor: Jilin University Not yet recruiting